ANI Pharmaceuticals, Inc.
ANIPHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, ANI Pharmaceuticals, Inc. (ANIP) is listed under Drug Manufacturers - Specialty & Generic. Valued at $1.64B, ANIP is a small-cap name in its sector. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Market Cap
$1.64B
Beta
0.45
P/E (TTM)
15.52
P/E (Fwd)
6.82
EPS (TTM)
$4.59
EPS (Fwd)
$10.44
ROE
20.5%
ROA
5.5%
Cash
$377.0M
Total Debt
$626.0M
Free CF
$132.2M
52W Change
-27.7%
Annual Financials
Cash vs Debt
Where ANIP stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, ANIP finished 5.55% below its 150-day moving average ($78.94) and 6.58% below its 200-day moving average ($79.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANIP overbought or oversold?
At the August 27, 2026 close, ANIP's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ANIP has $377.0M in cash with $626.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $132.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 20.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $316.4M (2022) to $883.4M (2025), reflecting a 179% increase over the period.
ANIP's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing ANIP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.